Moderna revealed the consequences of its late start in the market for RSV vaccines, reporting just $10 million in third-quarter sales from the new shot. Those numbers are a fraction ...
Sarepta Therapeutics is stopping development of vesleteplirsen, an experimental exon 51-skipping therapy for Duchenne muscular dystrophy patients with certain mutations. It's also halting work on all ...
California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug ...
Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...
Scientists have unveiled a strategy for targeting a vulnerability in tiny circles of floating DNA that can drive aggressive ...
In his first quarter leading CVS Health, CEO David Joyner laid out the initial steps he’s taking to rightsize the company, as ...
US presidential election winner Donald Trump has promised to let his ally Robert F. Kennedy Jr. “go wild” on drug and food policy. While Kennedy’s exact role in a potential ...
As former President Donald Trump returns to power — the Associated Press projected his presidential victory Wednesday morning — the biopharma industry may see the door open wider for more dealmaking, ...
It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field's next frontier: staving off the losses ...
Novo Nordisk disclosed several key updates from its cardiometabolic and hematology pipelines Wednesday as the drugmaker ...
Acadia Pharmaceuticals has sold its priority review voucher for $150 million, the company said Tuesday, but did not disclose the buyer … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback